The core activity of Laevoroc Oncology AG is the development and research of cancer immunotherapies, particularly the development of next-generation, game-changing immune-oncology therapies for the treatment of cancer, including brain tumors and hematological malignancies.
AI-generated
Offering
Products & services
Industry:Research & Development
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Development of next-generation cancer immunotherapies, in particular LR 09 as a PNP inhibitor for treating relapsed leukemia after allogeneic stem cell transplantation.
Development of neuro-oncology drugs
Development of innovative drugs for brain cancers; currently LR 02 as a selective ATR inhibitor with CNS penetration and a new mechanism of action based on synthetic lethality.
Development of chemotherapy drugs
Development of LR 06 and LR 06B, patented oral gemcitabine prodrugs for maintenance therapy in pancreatic, ovarian and breast cancers, including in combination therapies.
Knowledge
No knowledge articles yet
Once Laevoroc Medical AG has claimed this profile, we'll publish editorial articles and case studies here together.